Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales

Internal Medicine Journal

Volumn 37, Issue 8, 2007, Pages 569-571

  Sharma, R ^a   Koller, L ^a   Barclay, P ^b   Liddle, C ^a,c  

^a WESTMEAD HOSPITAL   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cost; Drug utilization evaluation; Off label; Rituximab

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HYDROCORTISONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; DATA BASE; DRUG COST; DRUG EFFICACY; DRUG USE; EVALUATION; GRAFT REJECTION; HUMAN; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; PATIENT MONITORING; PLASMAPHERESIS; POLYMYOSITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TEACHING HOSPITAL; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; AUSTRALIA; AUTOIMMUNE DISEASES; DRUG COSTS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS;

EID: 34447499050     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01406.x     Document Type: Article

References (12)

1. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997 25:705 8.
2. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000 6:443 6.
3. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994 83:435 45.
4. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004 4:996 1001.
5. Montgomery R, Simpkins CE, Zachary A, Lees L, Warren DS, Cooper M et al. Anti-CD20 rescue therapy for kidneys undergoing antibody-mediated rejection. Am J Transplant, 2004 4 suppl. 8:258.
6. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000 11 Suppl. 1:113 16.
7. Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005 46:191 6.
8. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005 56:29 44.
9. Savoldo B, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005 5:566 72.
10. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005 64:913 20.
11. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005 52:601 7.
12. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004 50:2580 89.